Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Annals of the Rheumatic Diseases|March 3, 2007
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialGerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, et al.
The Journal of Rheumatology|November 5, 2002
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritisAlfons den Broeder, Leo van de Putte, Rolf Rau, et al.
RMD Open|October 12, 2017
Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate aloneEdward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|December 27, 2014
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabDésirée van der Heijde, Maxime Breban, Dale Halter, et al.
RMD Open|September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumabGerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
Arthritis and Rheumatism|June 28, 2006
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trialDésirée van der Heijde, Alan Kivitz, Michael H Schiff, et al.
Arthritis and Rheumatism|September 30, 2008
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritisVictoria Bejarano, Mark Quinn, Philip G Conaghan, et al.
Clinical Rheumatology|October 12, 2012
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in JapanTomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi, et al.
Arthritis Care & Research|August 18, 2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim ResultsHermine I Brunner, Kabita Nanda, Mary Toth, et al.
Pageof 5